Infinity Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 15 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-22: Reporting owner Tasker Seth A; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-12-22: Reporting owner BLOCH LAWRENCE E; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-12-22: Reporting owner Perkins Adelene Q; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-10-16: Reporting owner Agresta Samuel; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-22 | Tasker Seth A Officer (Chief Business Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $2.14 exercise price | 2020-12-23 | |
| 2020-12-22 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +335,000 335,000 owned after | $2.14 exercise price | 2020-12-23 | |
| 2020-12-22 | Perkins Adelene Q Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +485,000 485,000 owned after | $2.14 exercise price | 2020-12-23 | |
| 2020-10-16 | Agresta Samuel Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $1.14 exercise price | 2019-10-16 | |
| 2020-06-17 | VENUTI MICHAEL C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-06-17 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-06-17 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-06-17 | BEIER DAVID W Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-06-17 | Agresta Samuel Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-06-17 | EVNIN ANTHONY B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.92 exercise price | 2020-06-18 | |
| 2020-03-16 | GAYNOR RICHARD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $0.69 exercise price | 2020-03-17 | |
| 2020-01-10 | Tasker Seth A Officer (Chief Business Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +412,500 412,500 owned after | $1.25 exercise price | 2020-01-13 | |
| 2020-01-10 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +418,750 418,750 owned after | $1.25 exercise price | 2020-01-13 | |
| 2020-01-10 | Kutok Jeffery Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +450,000 450,000 owned after | $1.25 exercise price | 2020-01-13 | |
| 2020-01-10 | Perkins Adelene Q Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +606,250 606,250 owned after | $1.25 exercise price | 2020-01-13 |